Tags

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,


“IS THERE A COVID VACCINE / CANCER CONNECTION?
The Highwire with Del Bigtree
First published at 20:54 UTC on September 24th, 2021.
Multiple sources in The HighWire’s network of Frontline Physicians, have reported an alarming uptick in aggressive cancers post-Covid vaccination. Could there be a link? Pathologist Ryan Cole, MD, discusses the available science and his lab’s findings.
#DrRyanCole #AmericasFrontLineDoctors #mRNAVaccine #VaccineInjury #TheHighwire #DelBigtree #HW234
Posted: September 24, 2021”
Link: https://www.bitchute.com/video/u4z9hU8nS8n4/

One article mentioned in the video, which links to and summarizes additional articles is “Coronavirus: Stabilising the Code”by Dr. Mike Williams, Sunday, 12th September 2021 Excerpt: “The fundamental change discovered by Weissman and Kariko was that nucleoside modification could protect mRNA from the body’s immune defences…” Read the article here: https://www.ukcolumn.org/index.php/article/stabilising-the-code

Kariko is a Hungarian researcher who met Weissman at the photocopy machine in 1998: http://web.archive.org/web/20210413004638/https://hungarianspectrum.org/2020/11/22/a-typical-hungarian-story-katalin-kariko/

Also, reactivation of dormant viruses is mentioned in the Williams article and the video: “Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series” By Victoria Furer, Devy Zisman, Adi Kibari, Doron Rimar, Yael Paran, Ori Elkayam Rheumatology, https://pubmed.ncbi.nlm.nih.gov/33848321/

Psichogiou, Mina et al. “Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2.” Vaccines vol. 9,6 572. 1 Jun. 2021 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228758/

Apparently, other viruses in the herpes virus family and wart viruses could be reactivated, as well.

In short, immune suppression is of concern with the BioNTech Pfizer vaccine, and presumably the other mRNA vaccines. For the viral vector vaccines, we don’t know. Even if the immune suppression is only temporary, the impacts can be very serious. We don’t know if the apparent suppression is temporary or permanent:

“Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. They are single-pass membrane-spanning receptors usually expressed on sentinel cells such as macrophages and dendritic cells, that recognize structurally conserved molecules derived from microbes. Once these microbes have breached physical barriers such as the skin or intestinal tract mucosa, they are recognized by TLRs, which activate immune cell responses. The TLRs include TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, though the last three are not found in humans,[1] and there isn’t a functional gene for TLR10 in mice. [2] TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are located on the cell membrane, whereas TLR3, TLR7, TLR8, and TLR9 are located in intracellular vesicles (because they are sensors of nucleic acids).[3]….” https://en.wikipedia.org/wiki/Toll-like_receptor
Recall that the vaccines by-pass the physical barriers, because they are injected.

Cigarette smoke exposure (even short-term) decreases interferon production and makes people more susceptible to Covid-19, according to this study: https://miningawareness.wordpress.com/2021/08/22/short-term-exposure-to-sars-cov-2-and-cigarette-smoke-reduces-immune-response-increasing-chance-of-covid-19-infection-and-severity-of-infection/

“IFNγ [Interferon gamma] has antiviral, immunoregulatory, and anti-tumor properties…

IFNγ, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoan infections. IFNγ is an important activator of macrophages and inducer of major histocompatibility complex class II molecule expression. Aberrant IFNγ expression is associated with a number of autoinflammatory and autoimmune diseases. The importance of IFNγ in the immune system stems in part from its ability to inhibit viral replication directly, and most importantly from its immunostimulatory and immunomodulatory effects. IFNγ is produced predominantly by natural killer cells (NK) and natural killer T cells (NKT) as part of the innate immune response, and by CD4 Th1 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops[11][12] as part of the adaptive immune response. IFNγ is also produced by non-cytotoxic innate lymphoid cells (ILC), a family of immune cells first discovered in the early 2010s.[13]…” https://en.wikipedia.org/wiki/Interferon_gamma

One of the papers referenced in the video is “The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses“, by Föhse et al., 2021. BNT162b2 is the Germany company BioNTech vaccine, which is being tested and produced in collaboration with Pfizer. Apparently BNT stands for BioNTech. Some other companies are also helping to produce it.

A few excerpts from the paper:

From the Summary: “Interestingly, however, the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 [Toll Like Receptor 4] and TLR7/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger.

In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines…”

From the article: “the pandemic has led to accelerated development of vaccines based on new technologies, such as mRNA- and viral vector-based vaccines (van Riel & de Wit, 2020).

One of the most widely used anti-COVID-19 vaccines in the world was developed by a collaboration between BioNTech and Pfizer (BNT162b2). This vaccine is based on a lipid nanoparticle–formulated, nucleoside-modified mRNA that encodes a prefusion stabilized form of the spike (S)-protein derived from the SARS-CoV-2 strain isolated early on in Wuhan, China (Walsh et al., 2020)…
While global vaccination campaigns against the SARS-CoV-2 infection are rolled out, major challenges remain, especially the spread of novel virus variants (Madhi et al., 2021)…
In this study, we assessed the effect of the BNT162b2 mRNA COVID-19 vaccine on both the innate and adaptive (humoral and cellular) immune responses…

The induction of tolerance towards stimulation with TLR7/8 (R848) or TLR4 (LPS) ligands by BNT162b2 vaccination may indicate a more balanced inflammatory reaction during infection with SARS-CoV-2, and one could speculate whether such effect may be thus useful to regulate the potential over-inflammation in COVID-19, one of the main causes of death (Tang et al., 2020). On the other hand, inhibition of innate immune responses may diminish anti-viral responses. Type I interferons also play a central role in the pathogenesis and response against viral infections, including COVID-19 (Hadjadj et al., 2020). With this in mind, we also assessed the production of IFN-α [Interferon gamma] by immune cells of the volunteers after vaccination.

Although the concentrations of IFN-α were below the detection limit of the assay for most of the stimuli, we observed a significant reduction in the production if IFN-α secreted after stimulation with poly I:C and R848 after the administration of the second dose of the vaccine (Figure 1H, 1I). This may hamper the initial innate immune response against the virus, as defects in TLR7 have been shown to result in and increased susceptibility to COVID-19 in young males (Van Der Made et al., 2020). These results collectively demonstrate that the effects of the BNT162b2 vaccine go beyond the adaptive immune system and can also modulate innate immune responses.

The effect of the BNT162b2 vaccination on innate immune responses may also indicate a potential to interfere with the responses to other vaccinations, as known for other vaccines to be as ‘vaccine interference’ (Lum et al., 2010; Nolan et al., 2008; Vajo, Tamas, Sinka, & Jankovics, 2010). Future studies are therefore needed to investigate this possibility, especially the potential interaction with the influenza vaccine: in the coming years (including the autumn of 2021) COVID-19 vaccination programs will probably overlap with the seasonal Influenza vaccination, so it is crucial to perform additional studies to elucidate the potential interactions and effects of the COVID-19 vaccines with the current vaccination schedules, especially for immunosuppressed and elderly individuals.

The generalizability of these results is subject to certain limitations. First, the number of volunteers in this study was relatively small, although in line with earlier immunological studies on the effects of COVID-19 vaccines. Second, our cohort consisted of healthcare workers, who are middle-aged and healthy, and future studies in elderly individuals and people with comorbidities and other underlying risk factors for severe COVID-19 infections need to be performed (Gao et al., 2021). Third, our study is performed only with individuals with a Western European ancestry. Therefore, the conclusions of our study should be tested in populations with different ancestry and alternative lifestyles since the induction of innate and adaptive immune responses is largely dependent on different factors such as genetic background, diet, and exposure to environmental stimuli which largely differ between communities around the globe.

In conclusion, our data show that the BNT162b2 vaccine induces effects on both the adaptive and the innate branch of immunity and that these effects are different for various SARS-CoV-2 strains. Intriguingly, the BNT162b2 vaccine induces reprogramming of innate immune responses as well, and this needs to be taken into account: in combination with strong adaptive immune responses, this could contribute to a more balanced inflammatory reaction during COVID-19 infection, or it may contribute to a diminished innate immune response towards the virus. BNT162b2 vaccine is clearly protective against COVID-19, but the duration of this protection is not yet known, and one could envisage future generations of the vaccine incorporating this knowledge to improve the range and duration of the protection. Our findings need to be confirmed by conducting larger cohort-studies with populations with diverse backgrounds, while further studies should examine the potential interactions between BNT162b2 and other vaccines….” (Emphasis our own.)

See the article and affiliations (link after authors and affiliations):
“The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses By F. Konstantin Föhse, Büsranur Geckin, Gijs J. Overheul, Josephine van de Maat, Gizem Kilic, Ozlem Bulut, Helga Dijkstra, Heidi Lemmers, S. Andrei Sarlea, Maartje Reijnders, Jacobien Hoogerwerf, Jaap ten Oever, Elles Simonetti, Frank L. van de Veerdonk, Leo A.B. Joosten, Bart L. Haagmans, Reinout van Crevel, Yang Li, Ronald P. van Rij, Corine Geurtsvan Kessel, Marien I. de Jonge, Jorge Domínguez-Andrés, Mihai G. NeteaAffiliations: 11
Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud, University Medical Center, Nijmegen, The Netherlands. Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands. Section Pediatric Infectious Diseases, Laboratory of Medical Immunology, and Radboud Center for Infectious Diseases, Radboudumc, Nijmegen, The Netherlands. Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM) & TWINCORE, joint ventures between the Helmholtz- Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany. Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands. Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany. It is made available under a Creative Commons license; the author/funder has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) This version posted May 6, 2021. See: https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1.full.pdf

HT: https://derkamerad.com/2021/10/01/απάτη-κορονοϊού-covid-19-hoax-δραματική-έξαρση/